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Safety and Efficacy of Recombinant 
Interferon-gamma-lb (rlFN-ylb)Immune 
Adjuvant in 20 Patients Receiving High-Dose 
Donor Granulocyte Transfusions (GTX): An 
Observational Study During 2000-2004 
A. Safdar*, G. Rodriguez, B. Lichtiger, R. Champ[in, 
E.J. Freireich, H.M. Kantarjian. 44.D. Anderson 
Cancer Center, Houston, TX, USA 
Background: Response to antimicrobia[ therapy 
alone is often sub-optimal in severely immuno- 
suppressed cancer patients with difficult-to-treat 
opportunistic infections (OIs). 
Methods: Patients receiving G-CSF donor primed 
(-5.5 × 10 l° per transfusion) GTX plus rIFN-y1 b were 
evaluated. 
Results: The mean age was 43±17y, 10 (50%) were 
men, 16 (80%) had acute leukemia, 3 (15%) MDS 
and APACHE -II score was 19+17 (range, 17-22). 
Most patients (n = 18, 90%) had relapse or refractory 
cancer. In 6 (30%) a[[ogeneic hematopoietic stem 
ceil transplantation (HSCT) recipients, GTX plus 
rlFN-ylb was given 594-100 (range, 12-372) days 
after transplantation. Seventeen patients (85%) 
had severe neutropenia during GTX plus cytokine 
therapy. In 19 patients (95%) with invasive fun- 
ga[ infection (IFI), 5 (25%) had possible, 3 (15%) 
probable and 8 of 11 (55%) with definitive IFI had 
disseminated systemic mycosis. One patient (5%) 
had refractory Pseudomonas sepsis. Eight patients 
(40%) were receiving >600 mg prednisone equiva- 
lent dose during GTX-cytokine therapy. Cytokine 
doses that accompanied 104-7 (range, 4-28) GTX 
included, 94-7 doses of rlFN-ylb (mean cumula- 
tive dose [c.d.] 11884-2621pg). Other concomi- 
tant cytokines were G-CSF 124-3 G-CSF doses 
(c.d. 71284-4721 pg) in 15 patients (75%) and GM- 
CSF 124-9 doses (c.d. 56244-4410pg) in 14 pa- 
tients (70%). In 2 patients with fever and one 
patient each with skin rash and transient dyspnea 
were attributed to GTX. In 8 patients, 3 each 
with fever, and reversible liver dysfunction, and 
1 each with fever, and tachycardia were considered 
rlFN-ylb associated adverse reactions. Four weeks 
after therapy, 9 patients (45%) had completed or 
partial response; another 3 (15%) had stable sys- 
temic mycosis. 
Conclusions: Adjuvant GXT plus rlFN-ylb ther- 
apy was tolerated without serious adverse reac- 
tions. Therapeutic efficacy needs further prospec- 
tive evaluation. 
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A Trial of Increasing Dose of Baculovirus- 
Expressed Trivalent Influenza HA Vaccine: 
Prospective, Randomized, Double-Blind Study 
in Adult Patients with B-Cell Non-Hodgkin's 
Lymphoma (NHL) 
A. Safdar*, A. Rodriguez, F.E. Luis, J.E. Romaguera, 
EB. Hagemeister, RW. McLaugh[in, L. Kwak, 
R.B. Couch. M.D. Anderson Cancer Center 
(MDACC), and Baylor College of Medicine (BCM), 
Houston, TX, USA 
Background: Response of conventional influenza 
vaccine is impaired in patients with hematologic 
cancer. We hypothesized that an increased close 
of the hemagg[utinin (HA) antigen may improve 
protective immune response in patients with NHL. 
A recombinant HA antigen (rHAO) was used for this 
test. 
Methods: Twenty-seven patients were random- 
ized to receive one of the four vaccines be- 
tween August 23 and October 23, 2004. The 
SV was commercially avai[ab[e triva[ent vac- 
cine from a single lot containing 15pg per 
0.5m[ each of the hemagg[utinin (HA) of in- 
fluenza A/Panama/2007/99 (H3N2), A/New Cale- 
donia/20/99 (H1N1) and B/Hong Kong/330/2001 
(Aventis Pasteur, USA). The rHA0 consisted of HA 
proteins expressed in insect (SF9) ceils by recom- 
binant bacu[ovirus. The HA genes used were the 
same as those in the SV vaccine. The rHA0 vaccine 
was given in three final concentrations as deter- 
mined in assays for total protein; these were 15 pg, 
45pg, and 135pg of HA per 0.5m[ dose. The pre-, 
4- and 8-week post-vaccination antibody titers 
were measured from coded specimens. Test viruses 
for hemagg[utination-inhibition antibody (HIA) as- 
says were the same as the vaccine viruses; the 
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same H1N1 and B viruses were used for neutralizing 
antibody (neut) tests but A/Moscow/10/99 (H3N2) 
(antigenica[[y similar to A/Panama/H3N2 virus) was 
used in influenza A/H3N2 tests. 
Results: See the table. A[[ outpatient clinic NHL 
patients were screened and those who had not 
received chemotherapy in <3 months and rituximab 
in <6 months were considered. Sp[enctomized pa- 
tients and those receiving systemic corticosteroids 
were excluded. There were no serous adverse re- 
actions noted in any of the 27 enrollees during 
a 6-month period following vaccination. Among 
influenza A/H1N1 and A/H3N2, higher doses were 
associated with increased strain-specific protective 
neutralizing antibody titers. Whereas, this benefi- 
cial effect was not seen in patients receiving higher 
doses of influenza B vaccine. 
Vaccine Dose A/H3 a A/H1 a B a 
Riseb/ GMT c Riseb/ GMT c Riseb/ GMT c 
No. (%) No. (%) No. (%) 
Standard 15 0/4 6.6 2/5 3.3 2/5 1.8 
(0) (40) (40) 
rHA0 15 1/5 7.9 0/4 2.8 1/6 2.5 
(20) (0) (17) 
rHA0 45 2/5 7.9 1/4 2.8 0/5 1.4 
(40) (25) (0) 
rHA0 135 3/5 11.5 2/3 4.0 2/4 2.7 
(60) (67) (50) 
aA/H3 = 4.5-7.5; A/H1 = <1-4; B = <1-2[og2. 
bRise: no. of enro[[ees with antibody rise = four-fo[d or greater. 
c Highest GMT ([og2) 4 or 8 weeks post-vaccination. 
Conclusions: These pre[iminary results indicate a 
potential rHA0 dose-escalation benefit for neutral- 
izing antibody response against influenza A virus. 
94 
Efficacy of High-Dose (100 mg daily) Caspofungin 
(HD-CASP) Combination Antifungal Therapy in 
Cancer Patients with Invasive Fungal Infections 
(IFIs): Case-Controlled Observational Analysis 
During 2002-2004 
A. Safdar*, G. Rodriguez, K.V.I. Ro[ston, 
H.M. Kantarjian, G.R Bodey, R.E. Champlain, 
D. Kontoyiannis, I.I. Raad. M.D. Anderson Cancer 
Center Houston, TX, USA 
Background: Pneumocandins exert concentration- 
dependent antifunga[ effect, therefore we sought 
to evaluate efficacy (complete or partial response, 
C-PR) of HD-CASP therapy in patients with systemic 
mycosis. 
Methods: IRB approval was obtained to review the 
charts of 97 patients with probable and proven 
IFIs. Conventional-dose (CD) CASP was 70mg fol- 
lowed by 50mg daily. Fisher exact or chi-square 
test and student's t-test or Wi[coxon rank sums 
test were used to assess categorical and continuous 
variables, respectively. 
Results: Among evaluated Cases (n = 34) and con- 
trois (n = 63) there were not statistically significant 
differences between the two groups respect to 
the patients characteristics such as age, acute or 
chronic leukemia, BMT, GVHD, relapsed or refrac- 
tory cancer, co morbidities including DM, COPD, 
CAD, CHF, ARF, hepatic dysfunction, APACHE-II 
score, >600 prednisone equivalent dose prior or 
during CASP therapy, neutropenia prior and dur- 
ing therapy, antifunga[ prophylaxis, probable and 
proven IFI and combination antifunga[ therapy. 
Logistic regression multivariate 4-weeks assess- 
ment showed no difference in response in HD- 
and CD-CASP treatment groups, however, 12 weeks 
assessment showed a significantly improved prob- 
ability of favorable treatment response in pa- 
tients who had received HD-CASP (OR 3.066, 95% Cl 
1.092-8.61, P = 0.00335). 
Parameter Cases (%) Controls (%) P value 
Lung IFI 24 (71) 58 (92) 0.005 
Disseminated IFI 10 (29) 5 (8) <0.05 
Non-Aspergi[[us lung IFI 7 (21) 4 (6) <0.05 
Prior antifunga[ therapy 24 (71) 21 (33) 0.0004 
CASP therapy days a 12.5 (74) 29 (138) 0.0024 
C-PR [4-week] 10 (29) 14 (22) 0.1 
C-PR [12-week] 15 (44) 18 (29) 0.1 
aOive as median (range). 
Conclusions: Despite presence of unfavorable pre- 
dictors patients receiving HD-CASP had improved 
probability of infection resolution. 
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Changing Trends of Bacteremia in Patients with 
Cancer: Analysis of 2080 Quantitative Blood 
Cultures During 1998 and 2004 
A. Safdar*, G. Rodriguez, M. Ba[akrishnan, 
J. Tarrand, K.V.I. Ro[ston. M.D. Anderson Cancer 
Center, Houston, TX, USA 
Background: The severity of bacteria[ bloodstream 
infections (BSI) appears to be related to quanti- 
tative bacteria[ levels (organism load), especially 
in neutropenic cancer patients. We sought to de- 
termine the trends in quantitative patterns of BSI 
caused by various bacteria in patients receiving 
care at our comprehensive cancer center. 
Methods: A retrospective analysis of a[[ consec- 
utive blood cultures processed by Dupont Iso- 
lator 10 System during 1998 and during 2004. 
Only one blood culture per patient per organ- 
ism was included. Quantitative bacteremia was 
